InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.33
(
0.48%
)
Bitcoin
58,028.00
(
-3.55%
)
Post# of 252484
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Mufaso

Send PM Follow Ignore
Followers 32
Posts 477
Boards Moderated 0
Alias Born 01/08/2008

Mufaso

Member Level

Re: None

Thursday, 03/28/2024 2:25:07 PM

Thursday, March 28, 2024 2:25:07 PM

Post# of 252484
VKTX Analyst praise has been strong but I thought this comment was especially noteworthy:

If approved, VK2735 would almost certainly become a blockbuster. William Blair analyst Andy Hsieh projects the drug could reach peak annual sales of around $14.4 billion in the U.S. with another $7.2 billion in sales in Europe.


If my math is correct, that would be $21.6B in peak sales!!! For reference, I believe Humira peak sales were in 2022 at $22B.

This was from this article-> 5 Things You Need to Know If You Buy Viking Therapeutics Stock Today

https://finance.yahoo.com/news/5-things-know-buy-viking-095000469.html

"People are best convinced by reasons they discover themselves"

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up